Effects of Endotoxin on Liver Smac Apoptosis Channel

To study the effect of endotoxin on liver apoptosis, L02 liver cells were cultured and passaged in vitro, and then stimulated by endotoxin at 10 mg/mL for 4, 8, 16 and 24 h respectively. Liver apoptosis was flow cytometrically and fluorescently detected. Immunohistochemistry was used to detect the delivery of smac and caspase9. The delivery of liver cell smac and the activity of caspase3 were measured by caspase3 assay kit. The hepatic failure models of rats were established by using D-galactosamine. The blood serum and liver tissues were collected for the detection of the liver function, the level of endotoxin and the activity of caspase3 by using chromogenic substrate limulus amebocyte lysate method （LAL） and caspase3 active assay kit. The expression of smac and caspase9 in liver cells was detected by Western blotting. With in vitro study, the L02 cells stimulated by LPS condensed into conglobation and formed apoptotic bodies. After those cells were stained by hoechst, the apoptotic cells displayed blue color under the fluorescent microscope. The apoptosis rate was increased over time and the apoptosis was mainly of advanced stage. Meanwhile, the rate of smac delivery and activity of caspase9 and caspase3 were increased on L02 cell membrane. In vivo, hepatic failure and obvious endotoxemia were induced by injection of more than 200 mg/kg D-GalN. Hepatic mitochondria smac was reduced with dosage of D-GalN and, on the contrary, the activity of caspase3 was increased. D-GalN at 200 mg/kg increased Caspase9 while D-GalN at 300 mg/kg decreased caspase9. Mitochondria signal channel plays an important role in the endotoxin-induced apoptosis of hepatic cells by promoting the release of smac from mitochondria to cytoplasm and activating caspase9 and caspase3 in its low-level channel.     

Effect of Allicin in Antagonizing Mice's Bladder Cancerin vitro and in vivo

Objective: To explore anti-tumor effect and mechanism of Allicin in treating murine bladder tumor. Methods: To observe Allicin's effect on MBT-2 tumor cells in vitro, 100 μg/ml Allicin was added to the tumor cell culture, and the morphology of tumor cells was observed by phase contrast microscope 6 hrs later. The direct effects of Allicin on tumor cell growth in vitro in the MTT Assay was also evaluated. To determine anti-tumor effect of Allicin in vivo, C3H/He mice were randomly grouped prior to initiation of experiment. The mice received 1×105 MBT-2 cells administered subcutaneously into the right posterior flank on the Day 0 the experiment started. Allicin was injected at the site near tumor transplantation on the Day 1. The mice were examined for tumor development and the tumors were measured in two dimensions with calipers twice a week. On Day 21 the tumors were resected and examined pathologically to see the immune response. Results: The observation of morphology of MBT-2 cells in vitro and MTT a     

Potent in Vivo Anti-tumor Activity of Isolated CD62 Llow Lymph Node Cells Sensitized in Vivo With tumor Lysate-pulsed DC-based Vaccines

Background DC are potent APC that can activate both CD4 and CD8 T cells in vitro and in vivo. Although the efficacy of DC-hased cancer vaccines is currently being evaluated in clinical trials, the systemic immune suppression in cancer patients negatively impacts the clinical benefit of this therapeutic approach. Therefore, in this study we tested the feasibility and anti-tumor effect of adoptive immunotherapy using in vitro-activated CD62Llow lymph node cells that were isolated from DC-vaccinated draining lymph nodes （VDLN）. Methods DC were prepared from BM cells and loaded with tumor lysate for inoculating into naive mice. Subsequently, the VDLN were removed and CD62 Llow cells in the VDLN population isolated, expanded in vitro by 5-day culture with IL-2 and immobilized anti-CD3 stimulation, then injected into mice with established pulmonary tumors. Eighteen days after treatment, mice were killed in order to enumeratepulmonary tumor nodes. Results DC phagocytosed the tumor lysate efficiently and induced detectable T-cell responses and significant cell expansion in the draining lymph nodes. After induction of maturation by LPS treatment, DC expressed higher levels of CD40, CD86 and MHC class Ⅱ molecules. When CD62Llow VDLN cells that had been isolated and expanded in vitro were transferred into tumor-bearing mice, as few as 3 ＊ 106 cells were able to cure metastatic pulmonary tumors in vivo. Conclusion DC-hased VDLN T cells are an important source of anti-tumor effector for adoptive immunotherapy. This study provides a novel and an effective protocol using T-cell adoptive immunotherapy for application in cancer patients; therefore, clinical trials based on this protocol may be warranted.     

EVALUATION OF THE ANTITUMOR ACTIVITY OF HUMAN IL-4 BY IN VITRO AND IN V1VO ASSAYS

The characteristics of rhuIL-4 induced cytotoxicity was detected in vitro by using ^51 Cr release assay and the anti-tumor activity of rhuIL-4 induced killer cell was evaluated in vivo by using a human tumor model in nudemice.huIL-4 can induce LAK activity from peripheral blood lymphocytes(PBMC) stimulated with phytohemagglutinin(PHA).Compared with the LAK activity induced by rhuIL-2,the cytotoxicity of the killer cells induced by rhuIL-4 to K562 and Raji cells was lower ,but that to TBL-E,a human lymphoid leukemia cell line established in our laboratory,and PHA-activated blast cells(PHA-blasts) was of similar magnitude.In the cytotoxicity assay using PHA-blasts,the addition of PHA increased the IL-4 induced killer cell cytotoxicity by 131%,but had no effect on IL-2-induced ki8ller cell cytotoxicity.This implies that IL-4 mainly induces CTL-like activity,while IL-2 mainly induces NK-like activity,An experimental human tumor model in nude mice was established by injection of TBL-E human leukemia cells.The anti-tumor activity of rhuIL-4 was evaluated by injection of haman LAK cells induced from PHA-blasts by rhuIL-2 rhuIL-4 and human cytokines into tumor-bearing nude mice.The results showed that human LAK cells effectively inhibit the tumorigenicity of TBL-E cells in nude mice with an inhibition rate of 61%.The antitumor effect of rhuIL-2 was better than that of rIL-4 ,and the antitumor effect of rhuIL-2 rhuIL-4 was similar to that of rhuIL-2 ,though the former delayed the occurence of tumors.Our data imply the potential application of human IL-4 in clinic,and provide an animal model to evaluate the anti-tumor activity of human cytokine(s) with species specificity.     

Effects of Betulinic Acid on Proliferation and Apoptosis in Jurkat Cells and Its In Vitro Mechanism

The anti-cancer effects of betulinic acid (BA) on Jurkat cells and its in vitro mechanism were examined by using MTT assay. Apoptosis was detected by using Hoechst33258 staining and annexin-Ⅴ/PI double-labeled cytometry. The effects of betulinic acid on the cell cycle of Jurkat cells were studied by propidium iodide method. RT-PCR and Western blotting were used to analyze the changes of cyclin D3, bcl-xl mRNA and protein levels in Jurkat cells after treatment with betulinic acid. Our results showed the proliferation of Jurkat cells was decreased in betulinic acid-treated group with a 24-h IC50 value being 70.00 μmol/L. Betulinic acid induced apoptosis of Jurkat cells in a time-and dose-dependent manner. The number of Jurkat cells treated with betulinic acid showed an increase in G0/G1 phase and decrease in S phase. After treatment with 0, 20, 60, 100 μmol/L betulinic acid for 24 h, the number of Jurkat cells was increased from (31.00±1.25)% to (58.84±0.32)% in G0/G1 phase, whereas it was decreased from (61.45±1.04)% to (35.82±1.95)% in S phase. PBMCs were less sensitive to the cytotoxicity of betulinic acid than Jurkat cells. The expressions of cyclin D3, bcl-xl mRNA and protein were decreased sharply in Jurkat cells treated with betulinic acid. It is concluded that betulinic acid is able to inhibit the proliferation of Jurkat cells by regulating the cell cycle, arrest cells at G0/G1 phase and induce the cell apoptosis. The anti-tumor effects of betulinic acid are related to the down-regulated expression of cyclin D3 and bcl-xl.     

Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice

Background Hepatocellular carcinoma (HCC) ranked the second among the causes of cancer mortality in China since the 1990s. Up to now, medication still plays an important role in the treatment of HCC. The therapies based on the allicin as a potential chemopreventive analog although is in its infancy at the present time, may have a significant role in the future management of HCC. Diallyl trisulfide (DATS) is a natural compound derived from garlic. In this study, we investigated the inhibitory effects of hepatic targeted polybutylcyanoacrylate nanoparticles of diallyl trisulfide (DATS-PBCA-NP) on orthotopic transplanted HepG2 hepatocellular carcinoma in nude mice. Methods DATS-PBCA-NP were detected by transmission electron microscope (TEM) and high-performance liquid chromatography (HPLC). The orthotopic transplantation HCC models were established by implanting HCC HepG2 xenograft bits under the envelope of the mice liver. Successful models (n＝29) were divided into 4 groups: normal saline (NS), empty nanoparticles (EN), DATS and DATS-PBCA-NP were intravenously administered to the mice respectively for 2 weeks. In vivo antitumor efficacy was evaluated by the measurement of tumor volume. Terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay and protein levels of apoptosis and cell proliferation proteins by immunoblotting in tumor tissues were performed to elucidate the possible mechanism.Results DATS-PBCA-NP possessed smooth and round appearance, dispersed well, and released in vitro in accord with double phase kinetics model. DATS-PBCA-NP changed the tissue/organ distribution of DATS in vivo. The successful rate of tumor implantation was 100%. Intravenous administration of DATS-PBCA-NP significantly retarded the growth of orthotopically transplanted hepatoma in BALB/c nude mice (compared with the other three groups, all P<0.05) without causing weight loss (P>0.05). TUNEL staining showed that the tumors from DATS-PBCA-NP treated mice exhibited a markedly higher apoptotic index compared with control tumors. Western blot analysis of tumor tissue revealed that the down-regulated expression of proliferation cell nuclear antigen (PCNA) and Bcl-2 proteins in DATS-PBCA-NP group, and there were no significant differences in the expression of Fas, FasL and Bax proteins among the four groups (P>0.05).Conclusions DATS-PBCA-NP has good prolonged release effect in vivo and hepatic-targeted activity, and significant anti-tumor effect on the orthotopic transplantation HCC model in mice in association with the suppression of proliferation and the induction of apoptosis of tumor cells. These advantages are probably due to their liver targeting characteristics and consequently bring a higher anti-tumor activity.     

THE INFLUENCE OF HUMAN SINGLE CHAIN INTELEUKIN-12 GENE TRANSDUCTION ON THE BIOLOGICAL BEHAVIOR OF HEPATOMA 7721 CELLS

Objective. To investigate the anti-tumor effects of human single chain interleukin-12 (hscIL-12). Method. pcDNA/hscIL-12 recombinant was transfected into human hepatic carcinoma cells (7721 cells) by lipofectin method. The 7721/hscIL-12 cells which secrete hscIL-12 stably, were obtained via G418 selection, and in vitro the influence of hscIL-12 gene transduction on the growth of tumor cells was evaluated by cellcycle analysis. In vivo, genetically engineered 7721 cells (7721/hscIL-12, 7721/pcDNA) and parental cells were implanted into BALB/c nude mice, respectively. 7721/pcDNA and 7721/hscIL-12 groups were divided into two sub-groups on day 8: one was administered with hPBL twice, 6 days at interval; the other was given equalvolume of PBS. Mice were sacrificed on day 26, and spleens and tumors were taken out for histologic assay. Results. hscIL-12 produced stably by 7721/hscIL-12 cells had bioactivity, and it was proved by Western blot, immunocytochemistry, and in situ hybridization. In vitro, compared with 7721 and 7721/pcDNA, the7721/hscIL-12 grew much more slowly. FACS assay showed apparent G1 arrest of 7721/hscIL-12 cells. In ani-mal experiment, on day 8 after inoculation, the tumors of 7721 and 7721/pcDNA group were up to 5 -7mm,while those of 7721/hscIL-12 group were 2 -4mm. When treated with hPBL, the tumor of 7721/hscIL-12 groupdisappeared completely. Histologically, the tumors from 7721/hscIL-12 without hPBL treatment had numerouslymphocyte infiltration, the tumor cells displayed depression looking, atrophy, focal necrosis and apoptosis, whereas the tumors of 7721 and 772l/pcDNA groups grew thrivingly.Conclusion. hsclL-12 transduced 7721 cells could induced significant antitumor immune response which resulted in tumor regression totally when the hPBL was inoculated, and also hscIL-12 has certain effects on mice immune system. These findings suggest that hscIL-12 and hscIL-12 gene therapy might have promising prospects in clinical application.     

苦参碱对小鼠H22细胞抗肿瘤作用的实验研究

目的:观察苦参碱在体内和体外的抗肿瘤作用.方法:MTT法检测苦参碱对小鼠腹水瘤细胞H22的体外杀伤作用;Annexin V-FITC/PI双标记法检测苦参碱对体外培养的H22细胞的诱导凋亡作用;在BALB/C小鼠H22移植瘤模型上观察苦参碱的体内抑瘤活性,透射电镜观察苦参碱治疗后荷瘤小鼠肝癌细胞的超微结构改变;免疫组化法检测荷瘤小鼠肝癌组织中Bcl-2、Bax蛋白表达.结果:苦参碱在体外能够明显抑制H22细胞的生长和增殖,并可诱导细胞凋亡;对小鼠肿瘤生长也有明显抑制作用,高、低浓度组抑瘤率分别为60.71%和62.53%;用药组小鼠肿瘤组织中,电镜下可见较为典型的细胞凋亡的形态学改变;肿瘤组织中Bcl-2蛋白表达明显降低,Bax蛋白表达增强,与荷瘤对照组相比有显著性差异(P＜0.01).结论:苦参碱在体内外对H22肿瘤细胞生长均有抑制作用,同时可促进肿瘤细胞表达Bax蛋白,抑制Bcl-2表达,诱导肿瘤细胞凋亡.     

ZBTB20基因干扰腺病毒的制备及功能鉴定

目的 制备靶向锌指蛋白ZBTB20基因的干扰腺病毒。方法 根据ZBTB20基因序列设计人鼠通用的干扰序列，定向克隆至腺病毒穿梭载体pShuttle-U6-GFP的BamHⅠ和HindⅢ位点。PmeⅠ酶切线性化的重组穿梭载体pShuttle-shZBTB20导入含有腺病毒载体pAdEasy-1的细菌，使同源重组产生重组腺病毒载体pAd-shZBTB20。用PacⅠ酶切线性化该重组腺病毒载体，转染293A细胞以包装腺病毒颗粒，用TCID50法鉴定病毒滴度，并在人肝癌Huh7细胞和小鼠肝脏组织中验证该病毒的干扰效率。结果 成功构建了人鼠通用的ZBTB20基因干扰腺病毒载体，获得高活性的ZBTB20干扰腺病毒Ad-shZBTB20，滴度为3.2x1010 IU/ml。该干扰腺病毒感染人肝癌细胞株96 h可使ZBTB20 mRNA降低至对照的20%；尾静脉注射7天后可显著下调肝脏内源性ZBTB20蛋白的表达，并使其靶基因甲胎蛋白mRNA表达水平升高200倍以上。结论 所制备的ZBTB20干扰腺病毒能有效抑制人和小鼠ZBTB20的蛋白表达及其生物学效应，为ZBTB20功能研究和干预应用提供技术手段。     

索拉菲尼诱导的肝癌耐药细胞株的建立及其生物学特性

目的建立索拉菲尼诱导的PLC/PRF/5和Huh7耐药细胞株,并研究其耐药细胞的生物学特性。方法通过药物敏感性实验CCK8法测定索拉菲尼的半数抑制浓度IC50值;采用体外间歇诱导法,使用PLC/PRF/5和Huh7各自IC50值作为筛选浓度,建立索拉菲尼诱导的耐药细胞株模型;Real time-PCR检测5种耐药基因(GST-π、LRP、MDR1、MRP、TopoⅡ)在耐药组和对照组中的表达差异;Western blot检测MAPK信号通路中关键信号因子细胞外调节蛋白激酶(extra-cellular regulated protein kinases,ERK)ERK1/2在不同组别细胞中的磷酸化水平差异。结果所筛选的PLC/PRF/5和Huh7耐药组细胞与对照组细胞相比较,其细胞生存率有显著性提高(P<0.05);5种耐药基因中MDR1的表达有显著性上调(P<0.05);索拉菲尼作用靶点的下游信号因子ERK1/2的磷酸化水平上调。结论成功地在体外建立索拉菲尼诱导的PLC/PRF/5和Huh7耐药细胞株,其耐药机制可能与ERK1/2的磷酸化水平上调导致耐药基因MDR1高表达有关。     

MTT法指导分离壁虎抗肿瘤活性成分的实验研究

目的 采用四氮唑盐（MTT）法指导壁虎抗肿瘤活性成分的分离,寻找壁虎抗肿瘤活性单体化合物,并初步观察其抗肿瘤作用.方法 常规培养人肝癌Bel-7402细胞、人肺癌Bel-95C细胞,在倒置显微镜下观察细胞形态及数量,采用MTT法检测多批次壁虎活性成分提取物对体外培养的肿瘤细胞株的生长抑制作用,计算肿瘤抑制率.结果 经过11批次重复药筛实验,逐步分梯次指导分离纯化,得到壁虎抗肿瘤活性单体化合物＂守宫咪唑衍生物＂.该化合物可明显抑制人肝癌Bel-7402细胞的生长,用药后前3d的抑瘤率分别为71.24%,91.37%,94.45%,在显微镜下发现肿瘤细胞变圆、体积变小.结论 用MTT法结合倒置显微镜观察细胞状态,指导中药壁虎抗肿瘤活性成分的提取分离,得到抗肿瘤作用明显的壁虎单体化合物.     

利用Tet-Off表达系统构建鞘磷脂合酶可调控高表达的Huh7肝癌细胞

 目的 利用Tet-Off表达系统构建鞘磷脂合酶（sphingomyelin synthase,SMS）可被Dox调控高表达的Huh7细胞,为进一步探讨SMS活性升高致动脉粥样硬化的机制打下基础（建立细胞模型）。方法 首先将Tet-Off调控质粒转染Huh7细胞构建Huh7-tTA细胞,然后再将含外源性人SMS基因（hSMS）的PTREE2hyg质粒转染Huh7-tTA细胞,经分离纯化成功构建可调控表达hSMS的Huh7单克隆细胞（命名为SMS细胞,SMS1和SMS2）。为了便于检测外源性hSMS,利用FLAG标记hSMS（SMS-FLAG）。结果 SMS细胞表达SMS-FLAG受不同剂量Dox调控,SMS mRNA测定结果显示: 0 ng/mL Dox剂量组较0.01 ng/mL和100 ng/mL Dox组均有显著升高（P<0.05和P<0.001）;0.01 ng/mL Dox组较100 ng/mL Dox组也有显著升高（P<0.05）。SMS蛋白测定结果相似于SMS mRNA结果。SMS酶活性测定结果显示0 ng/mL Dox组显著高于100 ng/mL Dx组（P<0.001）,而对照组（Huh7-tTA）、100 ng/mL Dox组和野生型Huh7细胞组之间差异均无统计学意义（P>0.05）。结论 利用Tet-Off体系成功构建SMS高表达可调控Huh7细胞,SMS细胞SMS高表达受Dox剂量调控。     

Foxg1抑制肝癌细胞血管形成及其机制

目的 通过干扰和过表达肝癌细胞中的Foxg1,探讨Foxg1对人脐静脉血管内皮细胞(human umbilical vein endothelial cells,HUVEC)血管生成能力的影响及其机制.方法 实验分为Hep3B干扰组、Hep3B对照组、Huh7过表达组和Huh7对照组,提取各组细胞条件培养基(conditional medium,CM);通过Transwell实验、管腔形成实验观察各组CM对HUVEC的迁移及管腔形成的影响;采用实时荧光定量PCR(RT-PCR)及Western blot检测血管内皮生长因子A(vascular endothelial growth factor A,VEGFA)在各组肝癌细胞中的mRNA及蛋白水平,酶联免疫吸附实验(ELISA)检测各组CM内VEGFA浓度;采用Western blot检测4组肝癌细胞AKT1、p-AKT1的蛋白水平.结果 Hep3B干扰组较Hep3B对照组CM的作用下,HUVEC细胞的迁移数显著增多(P＜0.01),Huh7过表达组较Huh7对照组CM的作用下,HUVEC细胞迁移数显著减少(P＜0.01);Hep3B干扰组CM的作用下,HUVEC细胞管腔形成数多于Hep3B对照组CM(P＜0.01),而Huh7过表达组CM的作用下,HUVEC细胞管腔形成数少于Huh7对照组CM(P＜0.01);Hep3B干扰组较Hep3B对照组VEGFA水平上调,Huh7过表达组较Huh7对照组VEGFA水平下调;Hep3B干扰组CM较Hep3B对照组CM的VEGFA水平上调,Huh7过表达组CM较Huh7对照组CM的VEGFA水平下调(P＜0.01);Hep3B干扰组较Hep3B对照组AKT1磷酸化水平升高,Huh7过表达组较Huh7对照组AKT1磷酸化水平降低.结论 Foxg1抑制肝癌血管生成的过程可能是通过抑制PI3K/Akt通路的激活下调VEGFA的表达来实现的.     

稳定表达小鼠PNPLA7的Huh7细胞系的构建

目的:构建稳定表达小鼠PNPLA7-Flag蛋白的人类肝癌细胞Huh7细胞系,观察小鼠PNPLA7在Huh7细胞中的过表达以及对Huh7细胞脂质含量的影响?方法:构建pCMV6 -PNPLA7-Flag真核表达载体,应用脂质体转染技术将该质粒导入Huh7细胞,随后通过G418筛选稳定表达的细胞系,运用Western blot方法检测PNPLA7蛋白表达;并通过油酸处理及油红染色观察过表达PNPLA7蛋白对Huh7细胞中脂质含量的影响?结果:成功获得2株稳定过表达PNPLA7-Flag的Huh7细胞系;Huh7细胞中过表达PNPLA7蛋白,在油酸处理后细胞内脂滴含量减少?结论:稳定表达小鼠PNPLA7的Huh7细胞系构建成功;小鼠PNPLA7在Huh7细胞中的表达会引起细胞中脂质含量减少,从而为后续研究PNPLA7蛋白在脂代谢通路的功能及机制提供可靠的细胞模型?     

miR-150-5p与NCAPG的靶向关系及其对肝细胞肝癌Huh7细胞的抑制作用

目的 探究miR-150-5p与非SMC凝聚体Ⅰ复合物亚基G（NCAPG）的靶向关系及其对肝细胞肝癌（HCC）细胞生物学功能的影响，为HCC的临床诊断和治疗提供潜在靶点。 方法 通过双荧光素酶报告基因实验验证miR-150-5p与NCAPG的靶向关系。将HCC Huh7细胞根据转染质粒不同分为模拟物阴性对照（mimic NC）组、miR-150-5p模拟物（miR-150-5p mimic）组、miR-150-5p模拟物+过表达阴性对照（miR-150-5p mimic+ovNC）组和miR-150-5p模拟物+过表达NCAPG（miR-150-5p mimic+ovNCAPG）组。实时荧光定量PCR（RT-qPCR）法检测各组细胞中NCAPG mRNA表达水平，Western blotting法检测各组细胞中NCAPG蛋白表达水平，5-乙炔基-2'-脱氧尿嘧啶核苷（EdU）实验检测各组细胞EdU阳性率，流式细胞术检测各组细胞凋亡率，Transwell实验检测各组细胞中迁移和侵袭细胞数。将裸鼠分为agomiR-NC组、agomiR-150-5p组、agomiR-150-5p+过表达阴性对照（agomiR-150-5p+ovNC）组和agomiR-150-5p+过表达NCAPG（agomiR-150-5p+ovNCAPG）组，Huh7细胞皮下成瘤，检测各组裸鼠肿瘤体积和质量。 结果 双荧光素酶报告基因实验证实NCAPG是miR-150-5p的靶基因。与mimic NC组比较，miR-150-5p mimic组Huh7细胞中NCAPG mRNA和蛋白表达水平及EdU阳性率明显降低（P<0.05），细胞凋亡率明显升高（P<0.05），迁移细胞数和侵袭细胞数明显减少（P<0.05）；与miR-150-5p mimic+ovNC组比较，miR-150-5p mimic+ovNCAPG组Huh7细胞中NCAPG mRNA和蛋白表达水平及EdU阳性率明显升高（P<0.05），细胞凋亡率明显降低（P<0.05），迁移细胞数和侵袭细胞数明显增加（P<0.05）。与agomiR-NC比较，agomiR-150-5p组裸鼠Huh7细胞移植瘤体积和质量明显减少（P<0.05）；与agomiR-150-5p+ovNC组比较，agomiR-150-5p+ovNCAPG组裸鼠Huh7细胞移植瘤体积和质量明显增加（P<0.05）。 结论 miR-150-5p通过靶向结合抑制NCAPG表达进而抑制HCC细胞增殖、迁移、侵袭和肿瘤生长，促进细胞凋亡。     

胡黄连苷Ⅱ对大鼠脑缺血再灌注损伤后炎症反应影响

目的研究胡黄连苷Ⅱ对大鼠脑缺血再灌注损伤后炎症反应的抑制作用。方法应用线栓法建立大鼠大脑中动脉闭塞再灌注模型,随机分为假手术组、模型组和治疗组,治疗组在缺血后2 h以微量注射器经尾静脉给予胡黄连苷Ⅱ(10 mg/kg)250μL,模型组和假手术组同步给予0.1 mol/L PBS 250μL。采用BEDERSON评分方法评价大鼠神经行为功能,采用氯化三苯基四氮唑染色观察大鼠脑梗死体积,采用原位TUNEL染色方法检测大鼠神经细胞凋亡情况,采用免疫荧光染色和Western Blotting方法检测大鼠脑组织基质金属蛋白酶-9(MMP-9)的表达。结果假手术组大鼠未出现行为功能异常,细胞凋亡数量较少,MMP-9表达较弱。模型组大鼠表现为神经行为功能障碍,缺血侧皮质和纹状体区出现梗死病灶,细胞凋亡数量增多,MMP-9表达增强。应用胡黄连苷Ⅱ干预治疗后,MMP-9表达较模型组显著降低,细胞凋亡数量明显减少,脑梗死体积显著减小,神经行为功能显著改善。结论胡黄连苷Ⅱ可抑制大鼠脑缺血再灌注损伤后炎症反应,对大鼠脑缺血再灌注损伤起到保护作用。     

抑癌基因Runx3增强顺铂致肝癌细胞的凋亡效应

目的:探讨腺病毒介导的Runx3基因(Ad-Runx3)与化疗药物顺铂(DDP)联合应用对肝癌细胞HLE增殖的抑制效果.方法:检测肝癌细胞HLE中Runx3基因启动子区域甲基化状态及表达情况.通过Ad-Runx3感染肝癌细胞HLE,利用RT-PCR方法检测Runx3基因在肝癌细胞中的转录,用Ad-Runx3联合化疗药物...